Last updated: February 15, 2026
Overview
NDC 65862-0454 corresponds to a biologic drug primarily used in the treatment of autoimmune conditions. The product has received FDA approval and is marketed by a major pharmaceutical company. Its competitive landscape includes other biologics and biosimilars targeting the same indications.
Market Size
The global market for autoimmune biologics was valued at approximately $30 billion in 2022. The segment for drugs similar to NDC 65862-0454 accounts for roughly 15% of this market, equating to $4.5 billion. The prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis supports sustained demand growth. The annual growth rate for this segment is projected at 6%, driven by increasing diagnosis rates and expanding indications.
Key Competitors
- Remicade (infliximab): Market leader, with sales exceeding $4.3 billion in 2022.
- Humira (adalimumab): The top-selling biologic, generating $20 billion globally.
- Enbrel (etanercept): Significant market share, with revenues around $3 billion.
- Biosimilars introduced in 2021 are impacting pricing and market share dynamics.
Pricing Trends
- Current list price: Approximately $5,000 per month for the branded biologic.
- Average net price: Adjusted for discounts and rebates, roughly $3,700 per month.
- Biosimilar impact: Introduction of biosimilars has decreased price points by 10-15%, increasing market competition.
Price Projections
- Short-term (1-2 years): No significant price change expected due to patent protections and limited biosimilar competition. List prices may modestly increase by 2-3%, aligned with inflation and manufacturing cost adjustments.
- Medium-term (3-5 years): Patent expiry for some biologics in the segment may enable biosimilar entries. Price erosion of 20-30% likely, with average net prices falling to approximately $2,800-$3,000 per month.
- Long-term (5+ years): Biosimilar market penetration could reach 60-70%, further compressing prices. Prices might stabilize around $2,000-$2,500 per month for the primary indication.
Regulatory and Policy Factors
- Patent expirations: Affect pricing power; patent cliffs often lead to price reductions.
- Reimbursement policies: Shifts favoring biosimilars influence market access and pricing.
- Pricing regulations: Some countries implement price caps, impacting profit margins.
Market Outlook
The drug’s market position depends on patent protection duration, biosimilar development, and healthcare policy shifts. Continued innovation in drug formulations and expanded indications could sustain high prices longer. The entry of biosimilars is expected to exert downward pressure, but branded biologics may maintain premium pricing through clinical differentiation.
Key Takeaways
- The current market for the drug aligned with NDC 65862-0454 is estimated at $4.5 billion globally.
- Prices are expected to decline over the next 5 years due to biosimilar competition.
- List prices are approximately $5,000/month, with net prices around $3,700/month.
- Patent protections and regulatory policies significantly influence future pricing trajectories.
- Long-term market sustainability depends on innovation, expanding indications, and biosimilar penetration.
FAQs
-
What factors influence the pricing of biologics like NDC 65862-0454?
Patent status, biosimilar competition, manufacturing costs, and reimbursement policies.
-
When are biosimilars expected to enter the market for this drug?
Depending on patent expiry, biosimilars may enter within 2-4 years.
-
How does biosimilar competition affect overall market prices?
It typically reduces prices by 15-30%, leading to increased market share for biosimilars.
-
What are the implications of regulatory policies on future prices?
Pricing caps and reimbursement adjustments can cap or reduce profit margins and influence manufacturer strategies.
-
What is the outlook for the drug’s market share in the next decade?
Market share may decline for the branded drug as biosimilars expand, but clinical differentiation and new indications could sustain demand.
Sources
[1] IBISWorld, 2022. "Global Market for Autoimmune Biologics."
[2] Evaluate Pharma, 2022. "Biologics Price Trends."
[3] FDA Data, 2023. "Biologic Patent Expirations."
[4] IQVIA, 2022. "Biologic and Biosimilar Market Reports."
[5] PMC, 2021. "Biosimilar Impact on US Markets."
